Who are Sparrow Pharma's investors?

Sparrow Pharma's investors include OrbiMed, RA Capital, RiverVest Venture Partners, US Venture Partners.

How much funding has Sparrow Pharma raised?

Sparrow Pharma has disclosed $73.3M raised across 4 rounds.

Where is Sparrow Pharma headquartered?

Sparrow Pharma is headquartered in Portland, US.

Sparrow Pharma

Portland, US · Founded 2013 · Delaware corporation · 17 employees on LinkedIn · 4 known investors

Find your way into Sparrow Pharma

499 people in our graph share verified history with the Sparrow Pharma team — schools, employers, funds. One of them is your warm intro.

Paul Kwanunlockedknows Robert Jacks · together at Stanford University (overlapped)

×11knows the team · via Stanford University

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease. Its lead program, clofutriben, is an HSD-1 inhibitor being evaluated in a Phase 2b trial for patients with inadequately controlled type 2 diabetes driven by elevated cortisol.

Biotech Healthtech Medical Devices

Founders & leadership

Robert Jacks inPresident & CEORobert Jacks is an executive with 25 years of experience in biopharmaceutical product development, strategy, business development, and finance. He has founded or co-founded multiple companies and has raised over $300 million with several successful exits.

David Aaron KatzNamed on SEC filing

Board

Jonathan Root inBoard directorGeneral Partner at US Venture Partners

Niall O'Donnell inBoard directorManaging Director at RiverVest Venture Partners

Zach Scheiner inBoard of DirectorsPartner at RA Capital

Klaus Veitinger inChairman of the BoardVenture Partner at OrbiMed

Nanna L?neborgBoard director

Peter Thompson inBoard directorInvestor at OrbiMed

Investors · 4

OrbiMedNew York · $1M – $75M

RA CapitalBoston

RiverVest Venture PartnersSt. Louis · $500K – $3M

US Venture PartnersMenlo Park · $500K – $10M

Reported raises · per SEC filings

Form D private placements

$73.3M disclosed across 4 rounds · 2018–2025

▶$61.8MraisedJul 2025 · 17 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Jonathan RootDirector
Niall O'DonnellDirector
Zach ScheinerDirector
Klaus VeitingerDirector
Nanna L?neborgDirector
Peter ThompsonDirector
Robert JacksExecutive Officer, Director

Offering amount: $121.4M
Amount sold: $61.8M
First sale: Jun 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10MraisedApr 2024 · 4 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Peter ThompsonDirector
Jonathan RootDirector
Klaus VeitingerDirector
Niall O'DonnellDirector
Robert JacksExecutive Officer, Director

Offering amount: $15.3M
Amount sold: $10M
First sale: Apr 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.1MraisedJan 2021 · 15 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

David KatzExecutive Officer
Robert JacksExecutive Officer, Director
Peter ThompsonDirector
Klaus VeitingerDirector

Offering amount: $50.8M
Amount sold: $1.1M
First sale: Dec 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$337.5KraisedJun 2020 · 10 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

David Aaron KatzExecutive Officer, Director

Offering amount: $337.5K
Amount sold: $337.5K
Minimum investment: $10K
Sales commissions: $675
Placement agents: Exemplar Capital, LLC
First sale: Aug 2018
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Eli Lilly20 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Aro Biotherapeutics13 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

Spero Therapeutics13 shared keywordsSpero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease. It focuses on immune signaling pathways involved in inflammation and fibrosis, with potential applications across additional immune-mediated conditions.

Companies competing with Sparrow Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Sparrow Pharma do?: Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease. Its lead program, clofutriben, is an HSD-1 inhibitor being evaluated in a Phase 2b trial for patients with inadequately controlled type 2 diabetes driven by elevated cortisol.
Who are Sparrow Pharma's investors?: Sparrow Pharma's investors include OrbiMed, RA Capital, RiverVest Venture Partners, US Venture Partners.
How much funding has Sparrow Pharma raised?: Sparrow Pharma has disclosed $73.3M raised across 4 rounds.
Where is Sparrow Pharma headquartered?: Sparrow Pharma is headquartered in Portland, US.